MWM
GPCR icon

Mission Wealth Management’s Structure Therapeutics GPCR Stock Holding History

Mission Wealth Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Hold
7,583
– – 0.01% 760
2026
Q1 		$366K Sell
7,583
-2,000
-21% -$137K 0.01% 568
2025
Q4 		$666K Hold
9,583
– – 0.01% 420
2025
Q3 		$268K Buy
+9,583
New +$191K 0.01% 613

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Mission Wealth Management's GPCR Position: Q2 2026 in Review

Mission Wealth Management held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 7,583 shares worth $407K. The position accounts for 0.01% of the portfolio, ranked #760.

Mission Wealth Management first reported a position in GPCR in Q3 2025 and has held it in 4 quarters since. The position peaked at $666K in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Mission Wealth Management held 7,583 shares of Structure Therapeutics worth $407K as of Q2 2026.
  • Mission Wealth Management left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up 0.01% of Mission Wealth Management's portfolio in Q2 2026, its #760 holding.
  • Mission Wealth Management first reported a position in Structure Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Mission Wealth Management's Structure Therapeutics position peaked at $666K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Mission Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.